Down 25% on Oct 29, and still 31% under its Oct 28 close.
ALNY's Quality Score fell 1 point on Wed, Nov 4, to 2. Trading went back to normal after a busy day (2 chart checks stopped).
Follow ALNY's trial news. Pro members can get an alert when Alnylam Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Long-term trend | −3 |
| Latest filing | 8-K, Oct 29 |
Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -13.7% on average, higher 1 of 4 times.
$3.3B in cash
No shelf registration or at-the-market program on file in the last three years.
EVP, CLO and Secretary Bryan Supran sold 1,758 shares on Oct 2. 23 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ALNY is #106 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 106 |
Share count against a year before: ALNY +2.3%, INSM +15%, REGN -2.2%.
Expected to report Thu Feb 11, before the open (in 99 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $15.72 a share, from $2.14.
“Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) –”
ALNY's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Net revenues from collaborations decreased during the three months ended September 30, 2026, as compared to the same period in 2025, primarily due to the recognition of $300.0 million of milestone revenue under our collaboration with Roche in September 2025 associated with the dosing of the first patient in the ZENITH Phase 3 clinical trial of zilebesiran.”
From its results filing (SEC filing · Oct 29)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | -20.1% | -25.1% | -30.7% |
| Jul 30, 2026 | -21.5% | -28.3% | -20.2% |
| Apr 30, 2026 | +2.1% | +2.8% | +0.6% |
Sales grew every year from 2018 to 2025, to $3.7B. It turned a profit in 2025 after a loss in 2024.
One insider sold $399K across 1 filing in the last 6 months. No open-market buys on record. The newest:
8 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ALNY is 0.1% of JEPQ, 0.1% of QQQ, and under 0.1% of QQQI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
“Competition in the pharmaceutical marketplace remains intense, with hundreds of companies competing to discover, develop, and market new drugs.”
ALNY scores 2 today, which Breakaway calls Below Average. It is #106 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 25% on Oct 29, and still 31% under its Oct 28 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ALNY scores 2 today, which Breakaway calls Below Average (0 to 5). That is #106 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ALNY's 2.
One insider sold $399K across 1 filing in the last 6 months. No open-market buys on record. The newest is Bryan Supran, EVP, CLO and Secretary, who sold $399K on Oct 2.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.